Geftinib tablets IP 250 mg

• When compared to carboplatin/paclitaxel combination chemotherapy, it lowers the risk of disease progression.
• When compared to carboplatin/paclitaxel combination chemotherapy, it improves median progression-free survival.
• When compared to other types of chemotherapy, it is well tolerated.